Jardiance® (empagliflozin) has changed its name to Empagliflozin
The packaging will look different, but the medicine inside is identical in every way: same active ingredient, same strength, same manufacturer, and same therapeutic effect.
Resource for your patients
Patient guide: Jardiance® to Empagliflozin
Support your adult patients with a clear, printable guide explaining the name change from Jardiance® to Empagliflozin. This resource helps reinforce conversations at the point of prescribing or collection.
Download and print this material for your patients where appropriate.
FAQs
Only the name and packaging. Jardiance® will now appear as Empagliflozin.
The medicine is the same Boehringer Ingelheim product – identical composition, manufacturing standards, quality, efficacy, and safety. There are no changes to clinical indications, dose, prescribing, or price. This is purely a branding update.
Please reassure patients that Jardiance® has simply changed its name to Empagliflozin. The packaging may look different, but the medicine inside is identical in every way: same active ingredient, same strength, same manufacturer, and same therapeutic effect.
- Empagliflozin Summary of Product Characteristics (SmPC).
PC-GB-112299 | April 2026
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing Empagliflozin.
- Empagliflozin UK Summary of Product Characteristics (SmPC).
Empagliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
Empagliflozin is indicated in adults for the treatment of chronic kidney disease.1
Empagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-112290 | April 2026